Share this to:

Support & Insight for the Autumn of Life

Namenda Sued for “Forced Switch” of Alzheimer’s Drug


Namenda® is a drug widely used to treat mid-stage Alzheimer’s. The government is suing Namenda’s manufacturer to stop them from discontinuing their current formulation. See why.

NYS Attorney General Eric Schneiderman alleges Namenda’s manufacturer is illegally driving patients to its newer patented drug, Namenda-XR, to avoid losses from cheaper generic alternatives coming out very soon.

Continued below video…

The manufacturer has announced plans to withdraw Namenda, which generates more than $1 billion in annual revenues, and convinced 40% of patients and prescribing physicians to switch to newer Namenda XR.

Mr. Schneiderman says the company is “manipulating vulnerable patients” to protect profits.

On the one hand, the company says its new drug, taken once daily instead of twice, is better. Called Namenda-XR®, it is a slow-release pill. You take it once a day and it slowly releases its medication over the course of 24 hours. This usually helps insure that a person always has the right amount of medication, with the fewest side effects.

On the other hand, the old formulation already works fine for many people and is less expensive. This will be especially true when the generic version, called memantine, hits drugstore shelves soon.

What exactly is Namenda’s manufacturer trying to do by taking regular Namenda off the shelf? Namenda’s CEO spelled it out clearly in a January conference call. CEO Brent Saunders said,

“We believe that by potentially doing a “Forced Switch”, we will hold onto a large share of our base users.”

“It’s very difficult for the generics, then, to reverse commute back…”

To learn more, read the article,

Patent Expiration May Trigger Namenda Shortage


  • CBS News
  • Associated Press
Notify of

1 Comment
Inline Feedbacks
View all comments
September 22, 2014 5:14 pm

I was very glad to read this as I can't take Namenda XR, only the regular formulation. It's about time government stepped in to halt tactics like this from pharmaceutical companies!!

B. Berger

B. Berger

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


Leqembi: An Alzheimer's Drug Worth Rooting For?
At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that pro...
Adlarity 2
Adlarity has 7 Advantages over Donepezil Tablets
FDA-approved ADLARITY is the once-weekly donepezil patch. See how it compares to donepezil / Aricept / Ebixa tablets ...
Common Alzheimer's Medications Slow Cognitive Decline
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to fiv...
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter